The stock of Vir Biotechnology Inc. (NASDAQ:VIR) increased by $0.22 on Tuesday to finish at $9.85, up 2.28 percent. The last five days have seen an average of 3,019,120 shares of common stock traded. 12 times new highs were reached in the current year, with a fall of -$15.46. The average number of shares traded over the last 20 days was 1,756,080, while the average volume over the last 50 days totaled 1,670,094.
VIR stock dropped -19.79% since last month. On 09/18/23, the company’s shares reached a one-month low of $9.47. The stock touched a high of $31.55 on 01/27/23, after rallying from a low of $9.47 in 52 weeks. The price of VIR stock has declined by -61.08% or -$15.46 this year, reaching a new high 12 times. Still, the stock price is down -68.78% from the 52-week high.
Insider Transactions
VIR stock investors should be aware that Vir Biotechnology Inc. (VIR) stock had its last reported insider trading activity 82 days ago on Jun 30. On Jun 30, Director SATO VICKI L sold 18,000 shares at $24.66 each. This transaction resulted in the insider making $443,916. On Jun 30, SVF Endurance (Cayman) Ltd sold 700 shares at a price of US$25.11. After the transaction, the insider now owns 16,684,041 shares. 10% Owner SVF Endurance (Cayman) Ltd had earlier sold 89,942 shares on Jun 29 for $25.18 a share. The transaction was completed for $2,264,731.
Valuation Metrics
Beta for the stock is 0.20. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 2.76, the price-to-book (PB) ratio of 0.73.
Financial Health
For the three months ended June 29, Vir Biotechnology Inc.’s quick ratio was 8.60, while its current ratio was 8.60, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 93.90% percent. Vir Biotechnology Inc.’s EBITDA margin for the year ended June 29 was 52.52%, whereas its operating margin stood at -64.00% for the same period. Based on annual data, it had gross profit of $1.47 billion and revenue of $1.62 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. VIR’s return on assets (ROA) during the last 12 months has been -10.10%. There was a 28.60% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -13.10%.
Earnings Surprise
According to Vir Biotechnology Inc.’s quarterly financial report for the quarter that ended June 29. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $3.8 million, while revenues rose by 1169.21% to $62.96 million. It was predicted that Vir Biotechnology Inc.’s quarterly earnings would be -$1.45, but it ended up being -$1.2, beating the consensus by -20.80%. EBITDA was -$213.44 million for the quarter. At the end of Vir Biotechnology Inc.’s most recent quarter ended June 29, its liabilities totaled 433.67 million, while its total debt was $131.35 million. Equity owned by shareholders amounts to $134.25 million.
Technical Picture
Here’s a quick look at Vir Biotechnology Inc.’s (VIR) price momentum from a technical perspective. As of 19 September, the RSI 9-day stood at 17.95%, suggesting the stock is oversold, with a 17.47% historical volatility rate.
The stochastic %K and %D were 5.80% and 4.02% respectively, while the average true range (ATR) was 0.45. Based on the 14-day stochastic reading of 10.56%, the RSI (14) reading is 19.61%. On the 9-day MACD Oscillator, the stock is at -0.58, and the 14-day reading is at -1.34.
Analyst Ratings
Vir Biotechnology Inc. (NASDAQ: VIR) was downgraded by BofA Securities to a a Neutral rating in its latest research report. The stock was previously rated as a a Buy. Analysts have assigned Vir Biotechnology Inc. (VIR) an Overweight rating. VIR is a stock that is recommended for selling by 0 brokerage firms, while 2 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 1 rate it overweight and 6 others recommend it as a buy.
What is VIR’s price target for the next 12 months?
The current consensus forecast for the stock is between $14.00 and $95.00, with a median target price of $23.50. In analyzing these forecasts, the average price target given by analysts for Vir Biotechnology Inc. (VIR) is $32.75.
